Salicylic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Salicylic Acid: From Topical Keratolytic Use to Papillary Conjunctivitis
One-Sentence Summary
Salicylic acid is a keratolytic compound commonly used topically (OTC/off-label internationally) for acne, psoriasis, corns, calluses and warts, but it is not TFDA-approved and not currently marketed in Taiwan. The TxGNN model predicts a possible association with Papillary Conjunctivitis, but this is a pure model prediction (L5) — there are currently zero clinical trials and zero publications supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not TFDA-approved (0 licenses on file); internationally known as an OTC/off-label topical keratolytic for acne, psoriasis, corns, calluses and warts |
| Predicted New Indication | Papillary Conjunctivitis |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L5 |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on available pharmacology profiling data, salicylic acid’s antiacne/keratolytic effect has traditionally been attributed to COX inhibition, but this proposed mechanism has not been substantiated by public bioactivity data — the compound’s only documented molecular target in this evidence pack is ASIC3 (acid-sensing ion channel 3), which is not the classically proposed target.
Papillary conjunctivitis involves conjunctival epithelial hyperplasia and localized inflammation. The repurposing rationale offered by the model is that salicylic acid’s keratolytic/anti-inflammatory properties could theoretically modulate papillary hyperplasia — but this is speculative. There is no confirmed MOA data linking salicylate signaling to conjunctival tissue, no ophthalmic formulation on record, and no history of human ocular use to support this pathway.
Given the absence of any mechanistic confirmation, clinical trials, or literature, this prediction should be treated as a hypothesis-generation signal only, not a validated repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Salicylic acid is not currently marketed in Taiwan — there are 0 TFDA licenses/registrations on file for this compound, and no approved indication text is available.
Safety Considerations
- Pharmacological Target Profile: Pharmacology data indicates binding activity at ASIC3 (acid-sensing ion channel 3, Entrez Gene 9311). This is derived from receptor/target profiling data, not a clinical drug-drug interaction, and its clinical relevance to repurposing is currently unclear.
Formal TFDA warning and contraindication data for this compound is not yet available (flagged as Blocking data gap DG001 — required before safety pre-assessment can proceed).
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate rests entirely on an L5 model-only prediction with no clinical trials, no literature, no confirmed MOA, and no marketing history in Taiwan (0 licenses). There is currently no independent evidence base to support advancing this indication.
To proceed, the following is needed:
- TFDA label/warning and contraindication data (Blocking gap, DG001) — required before any safety pre-assessment (S1) can begin
- Confirmed mechanism of action data (High-priority gap, DG002) to validate or refute the proposed mechanistic link
- Preclinical or mechanistic studies specifically evaluating salicylate activity in ocular/conjunctival tissue
- Any human exposure data (topical/ophthalmic) to assess feasibility of an ocular route, since no formulation or route compatibility data currently exists
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.